Ayeni, Oluwatosin A. http://orcid.org/0000-0002-1132-2860
Chiwambutsa, Shingirai
Chen, Wenlong Carl
Kapungu, Nyasha
Kanji, Comfort
Thelingwani, Roslyn
Murugan, Nivashni
Mathiba, Rofhiwa
Phakathi, Boitumelo
Nietz, Sarah
Ramiah, Duvern
O’Neil, Daniel S.
Jacobson, Judith S.
Ruff, Paul
Cubasch, Herbert
Chirwa, Tobias
Joffe, Maureen
Masimirembwa, Collen
Neugut, Alfred I.
Funding for this research was provided by:
National Institutes of Health (NIH/R01-CA19262701, R01-CA250012)
South African Medical Research Council (MRC-RFA-SHIP 01-2019)
National Cancer Institute of the National Institutes of Health (K12CA226330)
Article History
Received: 6 September 2022
Accepted: 2 December 2022
First Online: 20 December 2022
Declarations
:
: AIN has consulted for Otsuka, Eisai, GlaxoSmithKline, United biosource Corp, Hospira. He has support from Otsuka. He is on the medical advisory board of EHE Intl. All other authors declare that they have no conflict of interest.
: This study was approved by the University of the Witwatersrand Human Research Ethics Committee, and the Institutional Review Board of Columbia University in New York, NY.
: All women provided written or fingerprint-confirmed informed consent. The study was performed in accordance with the Declaration of Helsinki.